Roche Licenses Rona Obesity Therapy in Deal Worth Up to $1.2 Billion
Roche struck a deal with China's Rona Therapeutics for worldwide rights to an experimental therapy for obesity and metabolic diseases, with payments of up to $1.16 billion.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Roche licenses Rona Therapeutics’ ALK7 — targeting RNAi obesity drug candidate in deal worth up to $1.16 billion
Roche entered an exclusive worldwide license deal with Rona Therapeutics for an investigational ALK7-targeting RNAi therapy for obesity. Rona will receive up to USD 100 million in upfront and near-term milestone payments. Additional development, regulatory, and commercial milestones could reach USD 1.06 billion, with t